Diagnosis and treatment of POEMS syndrome

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

INTRODUCTION POEMS syndrome is a paraneoplastic disorder associated with an underlying plasma cell dyscrasia. The major clinical feature of the syndrome is a chronic progressive polyneuropathy with a predominant motor disability. The acronym POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) captures several dominant features of the syndrome. Important traits not included in the acronym include elevated levels of vascular endothelial growth factor (VEGF), sclerotic bone lesions, Castleman disease, papilledema, peripheral edema, ascites, effusions, thrombocytosis, polycythemia, fatigue, clubbing, and abnormal pulmonary function test. Other names for the syndrome include osteosclerotic myeloma, Crow-Fukase syndrome, and Takatsuki syndrome. Although the vast majority of patients have osteosclerotic myeloma, these same patients usually have only 5% bone marrow plasma cells or less (almost always monoclonal λ), and rarely have anemia, hypercalcemia, or renal insufficiency. These characteristics and the superior median survival differentiate POEMS syndrome from multiple myeloma. The complexity of the interaction of plasma cell dyscrasia and peripheral neuropathy (PN) became increasingly evident in 1956 with Crow's description of two patients with osteosclerotic plasmacytomas with neuropathy, and other “striking features,” which included clubbing, skin pigmentation, dusky discoloration of skin, white finger nails, mild lymphadenopathy, and ankle edema. As many as 50% of patients with osteosclerotic myeloma were noted to have PN in contrast to 1–8 of multiple myeloma patients. A syndrome distinct from multiple myeloma-associated neuropathy became to be recognized.

Original languageEnglish (US)
Title of host publicationTreatment of Multiple Myeloma and Related Disorders
PublisherCambridge University Press
Pages182-194
Number of pages13
Volume9780521515030
ISBN (Print)9780511551901, 9780521515030
DOIs
StatePublished - Jan 1 2008

Fingerprint

POEMS Syndrome
Multiple Myeloma
Paraproteinemias
Peripheral Nervous System Diseases
Edema
Skin Pigmentation
Giant Lymph Node Hyperplasia
Therapeutics
Crows
Thrombocytosis
Polycythemia
Papilledema
Skin
Plasmacytoma
Polyneuropathies
Respiratory Function Tests
Hypercalcemia
Nails
Plasma Cells
Ascites

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dispenzieri, A. (2008). Diagnosis and treatment of POEMS syndrome. In Treatment of Multiple Myeloma and Related Disorders (Vol. 9780521515030, pp. 182-194). Cambridge University Press. https://doi.org/10.1017/CBO9780511551901.014

Diagnosis and treatment of POEMS syndrome. / Dispenzieri, Angela.

Treatment of Multiple Myeloma and Related Disorders. Vol. 9780521515030 Cambridge University Press, 2008. p. 182-194.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dispenzieri, A 2008, Diagnosis and treatment of POEMS syndrome. in Treatment of Multiple Myeloma and Related Disorders. vol. 9780521515030, Cambridge University Press, pp. 182-194. https://doi.org/10.1017/CBO9780511551901.014
Dispenzieri A. Diagnosis and treatment of POEMS syndrome. In Treatment of Multiple Myeloma and Related Disorders. Vol. 9780521515030. Cambridge University Press. 2008. p. 182-194 https://doi.org/10.1017/CBO9780511551901.014
Dispenzieri, Angela. / Diagnosis and treatment of POEMS syndrome. Treatment of Multiple Myeloma and Related Disorders. Vol. 9780521515030 Cambridge University Press, 2008. pp. 182-194
@inbook{e71a751449d74b569082dbb6825a4a20,
title = "Diagnosis and treatment of POEMS syndrome",
abstract = "INTRODUCTION POEMS syndrome is a paraneoplastic disorder associated with an underlying plasma cell dyscrasia. The major clinical feature of the syndrome is a chronic progressive polyneuropathy with a predominant motor disability. The acronym POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) captures several dominant features of the syndrome. Important traits not included in the acronym include elevated levels of vascular endothelial growth factor (VEGF), sclerotic bone lesions, Castleman disease, papilledema, peripheral edema, ascites, effusions, thrombocytosis, polycythemia, fatigue, clubbing, and abnormal pulmonary function test. Other names for the syndrome include osteosclerotic myeloma, Crow-Fukase syndrome, and Takatsuki syndrome. Although the vast majority of patients have osteosclerotic myeloma, these same patients usually have only 5{\%} bone marrow plasma cells or less (almost always monoclonal λ), and rarely have anemia, hypercalcemia, or renal insufficiency. These characteristics and the superior median survival differentiate POEMS syndrome from multiple myeloma. The complexity of the interaction of plasma cell dyscrasia and peripheral neuropathy (PN) became increasingly evident in 1956 with Crow's description of two patients with osteosclerotic plasmacytomas with neuropathy, and other “striking features,” which included clubbing, skin pigmentation, dusky discoloration of skin, white finger nails, mild lymphadenopathy, and ankle edema. As many as 50{\%} of patients with osteosclerotic myeloma were noted to have PN in contrast to 1–8 of multiple myeloma patients. A syndrome distinct from multiple myeloma-associated neuropathy became to be recognized.",
author = "Angela Dispenzieri",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511551901.014",
language = "English (US)",
isbn = "9780511551901",
volume = "9780521515030",
pages = "182--194",
booktitle = "Treatment of Multiple Myeloma and Related Disorders",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Diagnosis and treatment of POEMS syndrome

AU - Dispenzieri, Angela

PY - 2008/1/1

Y1 - 2008/1/1

N2 - INTRODUCTION POEMS syndrome is a paraneoplastic disorder associated with an underlying plasma cell dyscrasia. The major clinical feature of the syndrome is a chronic progressive polyneuropathy with a predominant motor disability. The acronym POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) captures several dominant features of the syndrome. Important traits not included in the acronym include elevated levels of vascular endothelial growth factor (VEGF), sclerotic bone lesions, Castleman disease, papilledema, peripheral edema, ascites, effusions, thrombocytosis, polycythemia, fatigue, clubbing, and abnormal pulmonary function test. Other names for the syndrome include osteosclerotic myeloma, Crow-Fukase syndrome, and Takatsuki syndrome. Although the vast majority of patients have osteosclerotic myeloma, these same patients usually have only 5% bone marrow plasma cells or less (almost always monoclonal λ), and rarely have anemia, hypercalcemia, or renal insufficiency. These characteristics and the superior median survival differentiate POEMS syndrome from multiple myeloma. The complexity of the interaction of plasma cell dyscrasia and peripheral neuropathy (PN) became increasingly evident in 1956 with Crow's description of two patients with osteosclerotic plasmacytomas with neuropathy, and other “striking features,” which included clubbing, skin pigmentation, dusky discoloration of skin, white finger nails, mild lymphadenopathy, and ankle edema. As many as 50% of patients with osteosclerotic myeloma were noted to have PN in contrast to 1–8 of multiple myeloma patients. A syndrome distinct from multiple myeloma-associated neuropathy became to be recognized.

AB - INTRODUCTION POEMS syndrome is a paraneoplastic disorder associated with an underlying plasma cell dyscrasia. The major clinical feature of the syndrome is a chronic progressive polyneuropathy with a predominant motor disability. The acronym POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) captures several dominant features of the syndrome. Important traits not included in the acronym include elevated levels of vascular endothelial growth factor (VEGF), sclerotic bone lesions, Castleman disease, papilledema, peripheral edema, ascites, effusions, thrombocytosis, polycythemia, fatigue, clubbing, and abnormal pulmonary function test. Other names for the syndrome include osteosclerotic myeloma, Crow-Fukase syndrome, and Takatsuki syndrome. Although the vast majority of patients have osteosclerotic myeloma, these same patients usually have only 5% bone marrow plasma cells or less (almost always monoclonal λ), and rarely have anemia, hypercalcemia, or renal insufficiency. These characteristics and the superior median survival differentiate POEMS syndrome from multiple myeloma. The complexity of the interaction of plasma cell dyscrasia and peripheral neuropathy (PN) became increasingly evident in 1956 with Crow's description of two patients with osteosclerotic plasmacytomas with neuropathy, and other “striking features,” which included clubbing, skin pigmentation, dusky discoloration of skin, white finger nails, mild lymphadenopathy, and ankle edema. As many as 50% of patients with osteosclerotic myeloma were noted to have PN in contrast to 1–8 of multiple myeloma patients. A syndrome distinct from multiple myeloma-associated neuropathy became to be recognized.

UR - http://www.scopus.com/inward/record.url?scp=80855134060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855134060&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511551901.014

DO - 10.1017/CBO9780511551901.014

M3 - Chapter

AN - SCOPUS:80855134060

SN - 9780511551901

SN - 9780521515030

VL - 9780521515030

SP - 182

EP - 194

BT - Treatment of Multiple Myeloma and Related Disorders

PB - Cambridge University Press

ER -